Skip to main content
SpringerLink
Log in

Acute adriamycin-induced cardiotoxicity is exacerbated by angiotension II

  • Original Research
  • Published:
Cytotechnology Aims and scope Submit manuscript

Abstract

Adriamycin (ADR) increases the production of reactive oxygen species (ROS), which diminishes mitochondrial function. Angiotensin-II stimulates mitochondrial ROS generation. The aim of the study was to examine whether angiotensin converting enzyme (ACE) or renin inhibitors protect against ADR-induced mitochondrial function impairment. Rats were divided into five groups as control, ADR, co-treatment ADR with captopril, co-treatment ADR with aliskiren, co-treatment ADR with both captopril and aliskiren. Left ventricular function and blood pressures were assessed at the end of treatment period. Mitochondrial membrane potential (MMP) and ATP levels were determined. ADR treatment decreased the left ventricular pressure and increased the left ventricular end-diastolic pressure. ADR decreased MMP and ATP levels in myocyte mitochondria due to increasing oxidative stress. ADR decreased MMP and ATP levels due to increased oxidative stress in the heart. Inhibitors of ACE and renin caused the elevation of the decreased of MMP and ATP levels. The pathologic changes in electrocardiogram, blood pressure and left ventricular function were decreased by inhibition of Ang-II production. We concluded that inhibitors of angiotensin II are effective against ADR cardiotoxicity via the restoration of MMP and ATP production and prevention of mitochondrial damage in vivo.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  • Arozal W, Watanabe K, Veeraveedu PT, Thandavarayan RA, Harima M, Sukumaran V, Suzuki K, Kodama M, Aizawa Y (2010) Effect of telmisartan in limiting the cardiotoxic effect of daunorubicin in rats. J Pharm Pharmacol 62:1776–1783. doi:10.1111/j.2042-7158.2010.01196.x

  • Boucek RJ Jr, Miracle A, Anderson M, Engelman R, Atkinson J, Dodd DA (1999) Persistent effects of doxorubicin on cardiac gene expression. J Mol Cell Cardiol 31:1435–1446. doi:10.1006/jmcc.1999.0972

    Article  CAS  Google Scholar 

  • Boucek RJ Jr, Steele A, Miracle A, Atkinson J (2003) Effects of angiotensin-converting enzyme inhibitor on delayed-onset doxorubicin-induced cardiotoxicity. Cardiovasc Toxicol 3:319–329

    Article  CAS  Google Scholar 

  • Chandran K, Aggarwal D, Migrino RQ, Joseph J, McAllister D, Konorev EA, Antholine WE, Zielonka J, Srinivasan S, Avadhani NG, Kalyanaraman B (2009) Doxorubicin inactivates myocardial cytochrome c oxidase in rats: cardioprotection by Mito-Q. Biophys J 96:1388–1398. doi:10.1016/j.bpj.2008.10.042

  • Dagenais NJ, Jamali F (2005) Protective effects of angiotensin II interruption: evidence for antiinflammatory actions. Pharmacotherapy 25:1213–1229. doi:10.1592/phco.2005.25.9.1213

    Article  CAS  Google Scholar 

  • de Cavanagh EM, Inserra F, Ferder M, Ferder L (2007) From mitochondria to disease: role of the renin-angiotensin system. Am J Nephrol 27:545–553. doi:10.1159/000107757

    Article  CAS  Google Scholar 

  • Dursun N, Taskin E, Ozturk F (2011a) Protection against adriamycin-induced cardiomyopathy by carnosine in rats: role of endogenous antioxidants. Biol Trace Elem Res 143:412–424. doi:10.1007/s12011-010-8875-y

    Article  CAS  Google Scholar 

  • Dursun N, Taskin E, Yerer Aycan MB, Sahin L (2011b) Selenium-mediated cardioprotection against adriamycin-induced mitochondrial damage. Drug Chem Toxicol 34:199–207. doi:10.3109/01480545.2010.538693

    Article  CAS  Google Scholar 

  • Fisher PW, Salloum F, Das A, Hyder H, Kukreja RC (2005) Phosphodiesterase-5 inhibition with sildenafil attenuates cardiomyocyte apoptosis and left ventricular dysfunction in a chronic model of doxorubicin cardiotoxicity. Circulation 111:1601–1610. doi:10.1161/01.CIR.0000160359.49478.C2

    Article  CAS  Google Scholar 

  • Harake D, Franco VI, Henkel JM, Miller TL, Lipshultz SE (2012) Cardiotoxicity in childhood cancer survivors: strategies for prevention and management. Future Cardiol 8:647–670. doi:10.2217/fca.12.44

    Article  CAS  Google Scholar 

  • Ibrahim MA, Ashour OM, Ibrahim YF, El-Bitar HI, Gomaa W, Abdel-Rahim SR (2009) Angiotensin-converting enzyme inhibition and angiotensin AT(1)-receptor antagonism equally improve doxorubicin-induced cardiotoxicity and nephrotoxicity. Pharm Res 60:373–381. doi:10.1016/j.phrs.2009.05.007

    Article  CAS  Google Scholar 

  • Iqbal M, Dubey K, Anwer T, Ashish A, Pillai KK (2008) Protective effects of telmisartan against acute doxorubicin-induced cardiotoxicity in rats. Pharmacol Rep 60:382–390

    CAS  Google Scholar 

  • Montaigne D, Hurt C, Neviere R (2012) Mitochondria death/survival signaling pathways in cardiotoxicity induced by anthracyclines and anticancer-targeted therapies. Biochem Res Int 2012:951539. doi:10.1155/2012/951539

    Article  CAS  Google Scholar 

  • Monti M, Terzuoli E, Ziche M, Morbidelli L (2013) The sulphydryl containing ACE inhibitor Zofenoprilat protects coronary endothelium from Doxorubicin-induced apoptosis. Pharmacol Res 76:171–181. doi:10.1016/j.phrs.2013.08.003

    Article  CAS  Google Scholar 

  • Muller DN, Derer W, Dechend R (2008) Aliskiren-mode of action and preclinical data. J Mol Med (Berl) 86:659–662. doi:10.1007/s00109-008-0330-6

    Article  CAS  Google Scholar 

  • Nakamae H, Tsumura K, Terada Y, Nakane T, Nakamae M, Ohta K, Yamane T, Hino M. (2005) Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone. Cancer 104:2492–2498. doi:10.1002/cncr.21478

  • Nakamura T, Ueda Y, Juan Y, Katsuda S, Takahashi H, Koh E (2000) Fas-mediated apoptosis in adriamycin-induced cardiomyopathy in rats: in vivo study. Circulation 102:572–578

    Article  CAS  Google Scholar 

  • Octavia Y, Tocchetti CG, Gabrielson KL, Janssens S, Crijns HJ, Moens AL (2012) Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies. J Mol Cell Cardiol 52:1213–1225. doi:10.1016/j.yjmcc.2012.03.006

    Article  CAS  Google Scholar 

  • Okumura K, Jin D, Takai S, Miyazaki M (2002) Beneficial effects of angiotensin-converting enzyme inhibition in adriamycin-induced cardiomyopathy in hamsters. Jpn J Pharmacol 88:183–188

    Article  CAS  Google Scholar 

  • Ozdogan K, Taskin E, Dursun N (2011) Protective effect of carnosine on adriamycin-induced oxidative heart damage in rats. Anadolu Kardiyol Derg 11:3–10. doi:10.5152/akd.2011.003

    Article  Google Scholar 

  • Pfeffer JM, Pfeffer MA, Braunwald E (1985) Influence of chronic captopril therapy on the infarcted left ventricle of the rat. Circ Res 57:84–95

    Article  CAS  Google Scholar 

  • Rashikh A, Abul Kalam N, Akhtar M, Mahmood D, Pillai KK, Ahmad SJ (2011) Protective effects of aliskiren in doxorubicin-induced acute cardiomyopathy in rats. Hum Exp Toxicol 30:102–109. doi:10.1177/0960327110369819

    Article  CAS  Google Scholar 

  • Rashikh A, Ahmad SJ, Pillai KK, Kohli K, Najmi AK (2012) Aliskiren attenuates myocardial apoptosis and oxidative stress in chronic murine model of cardiomyopathy. Biomed Pharmacother 66:138–143. doi:10.1016/j.biopha.2011.11.020

    Article  CAS  Google Scholar 

  • Rashikh A, Pillai KK, Ahmad SJ, Akhtar M, Najmi AK (2013a) Aliskiren alleviates doxorubicin-induced nephrotoxicity by inhibiting oxidative stress and podocyte injury. J Renin Angiotensin Aldosterone Syst 14:14–22. doi:10.1177/1470320312459980

    Article  CAS  Google Scholar 

  • Rashikh A, Pillai KK, Najmi AK (2013b) Protective effect of a direct renin inhibitor in acute murine model of cardiotoxicity and nephrotoxicity. Fundam Clin Pharmacol. doi:10.1111/fcp.12054

    Google Scholar 

  • Roig Minguell E (2004) Clinical use of markers of neurohormonal activation in heart failure. Rev Esp Cardiol 57:347–356

    Article  Google Scholar 

  • Sacco G, Mario B, Lopez G, Evangelista S, Manzini S, Maggi CA (2009) ACE inhibition and protection from doxorubicin-induced cardiotoxicity in the rat. Vasc Pharmacol 50:166–170. doi:10.1016/j.vph.2009.01.001

    Article  CAS  Google Scholar 

  • Shi Y, Moon M, Dawood S, McManus B, Liu PP (2011) Mechanisms and management of doxorubicin cardiotoxicity. Herz 36:296–305. doi:10.1007/s00059-011-3470-3

    Article  CAS  Google Scholar 

  • Simmons TW, Jamall IS (1989) Relative importance of intracellular glutathione peroxidase and catalase in vivo for prevention of peroxidation to the heart. Cardiovasc Res 23:774–779

    Article  CAS  Google Scholar 

  • Singal PK, Iliskovic N, Li T, Kumar D (1997) Adriamycin cardiomyopathy: pathophysiology and prevention. FASEB J 11:931–936

    CAS  Google Scholar 

  • St-Jacques R, Toulmond S, Auger A, Binkert C, Cromlish W, Fischli W, Harris J, Hess P, Jie Lan, Liu S, Riendeau D, Steiner B, Percival MD (2011) Characterization of a stable, hypertensive rat model suitable for the consecutive evaluation of human renin inhibitors. J Renin Angiotensin Aldosterone Syst 12:133–145. doi:10.1177/1470320310392618

  • Taskin EDN (2014) Recovery of adriamycın induced mitochondrıal dysfunctıon in liver by selenium. Cytotechnology. doi:10.1007/S10616-014-9736-X

    Google Scholar 

  • Taskin E, Dursun N (2012) The protection of selenium on adriamycin-induced mitochondrial damage in rat. Biol Trace Elem Res 147:165–171. doi:10.1007/s12011-011-9273-9

    Article  CAS  Google Scholar 

  • Taskin E, Ozdogan K, Kunduz Kindap E, Dursun N (2014) The restoration of kidney mitochondria function by inhibition of angiotensin-II production in rats with acute adriamycin-induced nephrotoxicity. Ren Fail 36:606–612. doi:10.3109/0886022X.2014.882737

    Article  CAS  Google Scholar 

  • Tokarska-Schlattner M, Wallimann T, Schlattner U (2006) Alterations in myocardial energy metabolism induced by the anti-cancer drug doxorubicin. CR Biol 329:657–668. doi:10.1016/j.crvi.2005.08.007

    Article  CAS  Google Scholar 

  • Toko H, Oka T, Zou Y, Sakamoto M, Mizukami M, Sano M, Yamamoto R, Sugaya T, Komuro I (2002) Angiotensin II type 1a receptor mediates doxorubicin-induced cardiomyopathy. Hypertens Res 25:597–603

  • Venkatesan N, Ramesh CV, Jayakumar R, Chandrakasan G (1993) Angiotensin I converting enzyme activity in adriamycin induced nephrosis in rats. Toxicology 85:137–148

    Article  CAS  Google Scholar 

  • Wallace KB (2003) Doxorubicin-induced cardiac mitochondrionopathy. Pharmacol Toxicol 93:105–115

    Article  CAS  Google Scholar 

  • Wallace KB (2007) Adriamycin-induced interference with cardiac mitochondrial calcium homeostasis. Cardiovasc Toxicol 7:101–107. doi:10.1007/s12012-007-0008-2

    Article  CAS  Google Scholar 

  • Westermann D, Riad A, Lettau O, Roks A, Savvatis K, Becher PM, Escher F, Jan Danser AH, Schultheiss HP, Tschöpe C (2008) Renin inhibition improves cardiac function and remodeling after myocardial infarction independent of blood pressure. Hypertension 52:1068–1075. doi:10.1161/HYPERTENSIONAHA.108.116350

  • Xu M, Sheng L, Zhu X, Zeng S, Chi D, Zhang GJ (2010) Protective effect of tetrandrine on doxorubicin-induced cardiotoxicity in rats. Tumori 96:460–464

    CAS  Google Scholar 

  • Zhu SG, Kukreja RC, Das A, Chen Q, Lesnefsky EJ, Xi L (2011) Dietary nitrate supplementation protects against doxorubicin-induced cardiomyopathy by improving mitochondrial function. J Am Coll Cardiol 57:2181–2189. doi:10.1016/j.jacc.2011.01.024

    Article  CAS  Google Scholar 

Download references

Acknowledgments

The authors wish to thank to Prof. Dr. Cem SUER and Prof. Dr. Yunus DURSUN for helping statistical analysis of data. This work was supported by the Medical Research Council of Erciyes University (Grant number TSD-09-733).

Conflict of interest

The authors have no conflicts of interest to disclose.

Author information

Authors and Affiliations

  1. Department of Physiotherapy and Rehabilitation, School of Health Sciences, Istanbul Bilim University, Yazarlar Sokak No:17, 34394, Esentepe-Şişli/Istanbul, Turkey

    Eylem Taskin

  2. Department of Physiology, Faculty of Medicine, University of Erciyes, Kayseri, Turkey

    Elvan Kunduz Kindap, Kalender Ozdogan & Nurcan Dursun

  3. Department of Pharmacology, Faculty of Pharmacy, University of Erciyes, Kayseri, Turkey

    Mukerrem Betul Yerer Aycan

Authors
  1. Eylem Taskin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Elvan Kunduz Kindap
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kalender Ozdogan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mukerrem Betul Yerer Aycan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Nurcan Dursun
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Eylem Taskin.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Taskin, E., Kindap, E.K., Ozdogan, K. et al. Acute adriamycin-induced cardiotoxicity is exacerbated by angiotension II. Cytotechnology 68, 33–43 (2016). https://doi.org/10.1007/s10616-014-9748-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10616-014-9748-6

Keywords

Search

Navigation